Kura Oncology, Inc. KURA R2K
Healthcare · Biotechnology · United States
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
READ MORE ›$10.20
+79.26% 1Y
Market & Price
Market Cap
$905.50M
Current Price
$10.20
High / Low (52W)
$12.14 / $5.54
Beta
0.32
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.22
Price to Book
8.40
P/S
12.64
EV/EBITDA
-1.10
Dividend Yield
-
Profitability & Returns
ROCE
-44.55%
ROE
-124.74%
ROA
-28.44%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.83
EPS (TTM)
$-3.35
Balance Sheet & Liquidity
Debt/Equity
0.22
Quick Ratio
5.86
Current Ratio
6.15
Debt
$24.27M
Total Assets
$738.36M
Current Assets
$708.66M
Working Capital
$591.69M
Ownership
Promoter Holding
1.43%
Chg in Prom Hold
-
FII / Inst Holding
96.39%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$348.95M
Total Revenue (TTM)
$71.64M
EBITDA
$-316.60M
Free Cash Flow
$-129.83M
Operating Cash Flow
$-77.98M
Shares Outstanding
88.77M
Gross Margin
-
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-35.05%
Revenue (YoY)
29.50%
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -35.0% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KURA Kura Oncology, Inc. R2K | 10.20 | - | $905.50M | - | -44.55% | -124.74% | - | -35.05% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.11M | 15.29M | 20.75M | 17.34M | 18.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 262.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.11M | - | - | - | 18.00M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 78.81M | 87.95M | 100.75M | 103.55M | 96.82M |
| Operating Income | -4.14K | -5.24K | -4.76K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.45M | -56.40M | -59.88M | -64.70M | -72.67M | -80.00M | -86.27M | -78.81M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.58M | -65.51M | -73.56M | -80.18M | -72.63M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 382.00K | 391.00K | 393.00K | 346.00K | 336.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -57.20M | -66.12M | -74.12M | -80.93M | -73.33M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 226.00K | 0 | 0 | 71.00K | 8.00K |
| Net Income | -5.77K | -6.89K | -6.43K | -4.48M | -5.58M | -6.09M | -6.63M | -6.66M | -6.93M | -7.53M | -7.82M | -9.33M | -14.60M | -14.74M | -15.01M | -16.10M | -13.94M | -14.94M | -16.39M | -17.86M | -19.21M | -20.49M | -23.77M | -30.69M | -33.66M | -33.37M | -32.45M | -34.77M | -35.50M | -34.07M | -37.17M | -38.60M | -49.52M | -50.84M | -54.40M | -57.43M | -66.12M | -74.12M | -81.00M | -73.33M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.51 | -0.50 | -0.49 | -0.52 | -0.53 | -0.50 | -0.53 | -0.50 | -0.59 | -0.59 | -0.63 | -0.66 | -0.75 | -0.85 | -0.92 | -0.83 |
| R&D Expense | - | - | - | 2.60M | 3.35M | 3.64M | - | - | - | - | - | - | - | - | - | - | 10.38M | 11.44M | 12.54M | - | 12.57M | 13.70M | 16.60M | 20.32M | 21.07M | 22.37M | 20.91M | 24.26M | 24.97M | 25.19M | 28.18M | 29.33M | 36.27M | 39.73M | 41.70M | 55.97M | 62.78M | 67.91M | - | 65.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 53.88M | 67.48M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 57.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 53.88M | 67.42M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 139.87M | 165.80M | 247.08M | 371.06M |
| Operating Income | - | - | - | -20.51K | -23.44K | -22.34K | -22.73K | -23.91K | - | - | - | - | - | - | - | -139.87M | -165.80M | -193.19M | -303.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -134.85M | -150.23M | -169.50M | -275.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 229.00K | 1.55M | 1.62M | 1.51M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -135.84M | -152.63M | -171.97M | -278.37M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 2.02M | 297.00K |
| Net Income | -14.98K | -33.62K | -20.00K | -22.39K | -27.04K | -27.32K | -28.61K | -30.73K | -22.62M | -27.56M | -35.43M | -60.45M | -63.14M | -89.62M | -130.47M | -135.84M | -152.63M | -173.98M | -278.67M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 26.43M | 46.79M | 47.83M | 60.40M | 84.72M | 92.81M | 115.23M | 169.97M | 251.07M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 29.50% |
Compounded Profit Growth
| 5 Years: | -35.05% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +79.26% |
| 6 Months: | -12.07% |
| 3 Months: | +16.84% |
| 1 Month: | +16.57% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2007 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Sep 2011 | Dec 2011 | Sep 2012 | Dec 2012 | Dec 2013 | Aug 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | 8.30K | 9.07K | - | 1.38M | 87.26M | 69.82M | 95.85M | 182.38M | 241.97M | 647.21M | - | 456.31M | 448.94M | 760.16M | 738.36M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 446.43M | 432.48M | 744.83M | 708.66M |
| Cash & Equivalents | 0 | - | - | 11.14K | 26.90K | 6.16K | 4.22K | 5.59K | 4.80K | 6.57K | - | 1.12M | 15.44M | 9.72M | 11.43M | 16.12M | 26.14M | 325.49M | - | 51.80M | 37.32M | 224.46M | 149.10M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 413.00K |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.06M | 8.80M |
| Total Liabilities | - | - | - | - | - | - | - | - | 103.65K | 133.03K | - | 4.81M | 5.16M | 12.95M | 15.99M | 21.39M | 23.19M | 36.31M | - | 36.03M | 51.66M | 346.52M | 564.23M |
| Current Liabilities | - | - | - | - | 70.39K | - | 74.75K | - | 103.65K | - | - | 3.02M | 5.05M | 5.45M | 10.03M | 13.62M | 15.56M | 26.02M | - | 24.06M | 35.26M | 78.71M | 116.97M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.32M | 5.57M | 7.50M | 7.25M | 4.25M | - | 9.16M | 9.33M | 6.92M | 9.71M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.02M | 17.20M | 16.59M | 20.46M |
| Total Equity | 0 | 35.02K | 1.40K | -18.60K | -40.99K | - | -68.03K | - | -95.35K | -123.96K | 0 | -3.43M | 82.10M | 56.88M | 79.86M | 160.99M | 218.78M | 610.90M | - | 420.28M | 397.27M | 413.64M | 174.13M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 68.31M | 74.35M | 78.23M | 87.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.24K | -22.68K | -24.42K | -23.23K | -15.96K | - | -28.44M | -48.66M | -54.76M | -69.83M | - | -110.06M | -124.82M | 134.32M | -64.06M |
| Investing Cash Flow | - | - | - | - | - | - | -23.42M | -79.30M | -46.33M | -99.94M | - | 32.63M | 15.56M | -101.59M | -13.10M |
| Financing Cash Flow | 35.00K | 0 | 25.00K | 25.00K | 15.00K | - | 53.57M | 132.64M | 111.10M | 469.33M | - | 38.56M | 94.78M | 154.42M | 1.79M |
| Capital Expenditure | - | - | - | - | - | -64.00K | - | - | - | -2.17M | - | -626.00K | -168.00K | -472.00K | -6.64M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | -72.00M | - | -110.69M | -124.99M | 133.84M | -70.70M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -38.87M | -14.48M | 187.14M | -75.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100.0% | 99.9% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -358.5% | -449.9% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -322.9% | -412.9% |
| ROE % | -42.8% | -2,401.6% | 107.5% | 54.6% | 39.7% | 28.6% | 23.1% | 0.9% | -27.6% | -48.5% | -44.4% | -37.5% | -28.9% | -14.7% | - | -32.3% | -38.4% | -42.1% | -160.0% |
| ROCE % | - | - | - | - | - | 23.4% | - | 1.5% | - | - | - | - | - | - | - | -32.4% | -40.1% | -28.4% | -48.9% |
Shareholding Pattern
Insiders
1.43%
Institutions
96.39%
Public Float
97.78%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.86% | 9.64M | $98.30M |
| 2 | Suvretta Capital Management, LLC | 9.66% | 8.58M | $87.47M |
| 3 | BVF Inc. | 9.51% | 8.45M | $86.15M |
| 4 | State Street Corporation | 5.08% | 4.51M | $46.02M |
| 5 | Vanguard Capital Management LLC | 4.26% | 3.79M | $38.61M |
| 6 | Armistice Capital, LLC | 4.21% | 3.74M | $38.11M |
| 7 | Prosight Management, Lp | 3.78% | 3.36M | $34.24M |
| 8 | Deep Track Capital, Lp | 2.98% | 2.64M | $26.96M |
| 9 | AQR Capital Management, LLC | 2.39% | 2.12M | $21.67M |
| 10 | Geode Capital Management, LLC | 2.29% | 2.03M | $20.75M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KURA
No recent headlines available.